+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country

Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country

Medical Journal of Australia 194(11): 602-604

In 2010, an immigrant from Burma was the first person to be diagnosed in New Zealand with extensively drug-resistant tuberculosis (XDR-TB). The strain of Mycobacterium tuberculosis is the most resistant reported to date in Australasia. Key difficulties of managing this disease in a low-prevalence country were delays from drug-susceptibility testing and in acquiring appropriate medicines, and a lack of evidence-based guidelines. Solutions are needed for New Zealand and the wider region as more cases of XDR-TB are likely to be encountered in the future.

(PDF emailed within 1 workday: $29.90)

Accession: 053164218

Download citation: RISBibTeXText

PMID: 21644877

Related references

Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infectious Disease Clinics of North America 24(3): 705-725, 2010

A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country. International Journal of Mycobacteriology 5(2): 128-134, 2016

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal 44(3): 811-815, 2015

Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Canadian Journal of Infectious Diseases & Medical Microbiology 19(2): 169-172, 2009

Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin). Journal of the College of Physicians and Surgeons--Pakistan 25(5): 337-341, 2016

Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran. Iranian Red Crescent Medical Journal 14(1): 53-55, 2012

Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian Journal of Medical Research 130(4): 392-395, 2010

The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Canadian Journal of Infectious Diseases & Medical Microbiology 18(5): 289-291, 2008

Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe. Tuberculosis Research and Treatment 2014: 349141-349141, 2014

Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China. Antimicrobial Agents and ChemoTherapy 57(8): 3857-3863, 2014

Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clinical Medicine 14(3): 279-285, 2014

Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Review of Anti-Infective Therapy 6(5): 713-724, 2008

Improving knowledge and awareness about tuberculosis in a middle incidence country such as Croatia as a potential response to extensively drug-resistant tuberculosis global spread. Lijecnicki Vjesnik 129(5): 164-165, 2007

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal 48(3): 938-943, 2016

Extensively drug-resistant tuberculosis: current challenges and threats. Fems Immunology and Medical Microbiology 53(2): 145-150, 2008